Physician profile
Amber Cano
NPI 1518618057
$9,371.69
in general payments reported to CMS, 2019-2025
64 companies · $3,447 in 2025
The $3,447 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,019 · 2023: $1,303 · 2024: $3,603 · 2025: $3,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,469 · Education: $484 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,468.74 |
| Education | $484.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $623.51 | 2023-2024 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals Lp | $588.92 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $532.77 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Daiichi Sankyo INC. | $473.15 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $441.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $424.80 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $400.46 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $371.84 | 2022-2025 | |
| Abbvie INC. | $312.35 | 2023-2025 | |
| Lilly USA, LLC | $306.81 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $305.03 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Aveo Pharmaceuticals, INC. | $288.25 | 2022-2025 | Fotivda |
| Genzyme Corporation | $261.49 | 2022-2025 | |
| Genentech USA, INC. | $252.65 | 2023-2025 | Polivy, Alecensa, Rozlytrek |
| Alexion Pharmaceuticals, INC. | $200.92 | 2022-2025 | Ultomiris |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $198.79 | 2022 | |
| Celgene Corporation | $197.36 | 2022-2025 | Reblozyl |
| Eisai INC. | $178.86 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.31 | 2022-2025 | |
| Genmab U.S., INC. | $158.17 | 2024-2025 | Tivdak |
| Emd Serono, INC. | $148.46 | 2022-2025 | Tepmetko, Bavencio |
| Stemline Therapeutics INC. | $144.75 | 2023-2025 | Orserdu |
| Array Biopharma INC | $140.65 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $136.12 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $134.36 | 2023-2025 | Vyloy, Xospata, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $127.72 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Epizyme, INC. | $124.49 | 2022 | |
| Tempus Ai, INC | $120.64 | 2024 | |
| Geron Corporation | $111.34 | 2024-2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $109.77 | 2022-2025 | Opdivo, Opdualag |
| Rigel Pharmaceuticals, INC. | $96.56 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $96.15 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $93.77 | 2024-2025 | Libtayo |
| Sobi, INC | $78.04 | 2023-2025 | |
| Tersera Therapeutics LLC | $73.38 | 2024-2025 | Zoladex |
| Pharmaessentia USA Corporation | $71.84 | 2025 | Besremi |
| Seagen INC. | $66.18 | 2022-2023 | Tukysa |
| Taiho Oncology, INC. | $65.55 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.75 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $52.31 | 2022-2023 | Epkinly, Imbruvica |
| Blueprint Medicines Corporation | $51.95 | 2024-2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $49.41 | 2024-2025 | Qinlock, Romvimza |
| Puma Biotechnology, INC. | $44.42 | 2022-2024 | |
| Beone Medicines USA, INC. | $41.58 | 2025 | Tevimbra |
| Sun Pharmaceutical Industries INC. | $39.09 | 2024 | |
| Agios Pharmaceuticals, INC. | $35.77 | 2024 | Pyrukynd |
| Karyopharm Therapeutics INC. | $32.50 | 2024-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $30.94 | 2023-2025 | Clonoseq |
| Kite Pharma, INC. | $25.73 | 2025 | Yescarta |
| Progenics Pharmaceuticals, INC. | $25.28 | 2024 | |
| Springworks Therapeutics, INC. | $24.22 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $22.69 | 2024 | Poteligeo |
| Nuvation Bio INC. | $22.02 | 2025 | Ibtrozi |
| Coherus Oncology, INC. | $21.89 | 2024 | |
| Beigene USA, INC. | $21.17 | 2025 | Tevimbra |
| Clovis Oncology, INC. | $21.09 | 2022 | |
| G1 Therapeutics, INC. | $19.66 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.49 | 2022 | |
| Hologic Sales and Service, LLC | $19.21 | 2022 | |
| Novocure INC. | $17.35 | 2025 | Optune Lua (Novottf-200t) |
| Legend Biotech USA INC. | $16.91 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $15.25 | 2025 | Ojjaara |
| Iovance Biotherapeutics, INC. | $14.56 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.